Aggressive non-Hodgkin's lymphoma: Economics of high-dose therapy

High-intermediate grade non-Hodgkin's lymphoma (NHL) is an aggressive form of the disease, which can respond well to combination chemotherapy, with long-term survival seen in 40-50% of patients. When NHL relapses following standard treatment, high-dose chemotherapy with peripheral blood stem ce...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics 2004-01, Vol.22 (4), p.207-224
Hauptverfasser:	BEARD, Stephen M, WALL, Lucy, GAFFNEY, Louise, SAMPSON, Fiona
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - economics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Bone Marrow Transplantation - economics Chemotherapy Clinical Trials as Topic Combined Modality Therapy - economics Dose-Response Relationship, Drug Economy. Management Health and social institutions Health technology assessment Humans Lymphoma, Non-Hodgkin - drug therapy Lymphoma, Non-Hodgkin - economics Lymphoma, Non-Hodgkin - therapy Medical sciences Pharmacology. Drug treatments Public health. Hygiene Public health. Hygiene-occupational medicine Quality of Life Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!